{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:38:11Z","timestamp":1791999491679,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2003,5,30]],"date-time":"2003-05-30T00:00:00Z","timestamp":1054252800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1038\/sj.npp.1300251","type":"journal-article","created":{"date-parts":[[2003,8,6]],"date-time":"2003-08-06T07:55:14Z","timestamp":1060156514000},"page":"2000-2009","source":"Crossref","is-referenced-by-count":292,"title":["Effects of Buprenorphine Maintenance Dose on \u03bc-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers"],"prefix":"10.1038","volume":"28","author":[{"given":"Mark K","family":"Greenwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris-Ellyn","family":"Johanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Kilbourn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Koeppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon-Kar","family":"Zubieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,5,30]]},"reference":[{"key":"BF1300251_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1037\/1064-1297.3.4.477","volume":"3","author":"WK Bickel","year":"1995","unstructured":"Bickel WK, Amass L (1995). Buprenorphine treatment of opioid dependence: a review. Exp Clin Psychopharmacol 3: 477\u2013489.","journal-title":"Exp Clin Psychopharmacol"},{"key":"BF1300251_CR2","first-page":"47","volume":"247","author":"WK Bickel","year":"1988","unstructured":"Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988). Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 247: 47\u201353.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300251_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/jcbfm.1993.6","volume":"13","author":"RE Carson","year":"1993","unstructured":"Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC et al (1993). Comparison of bolus and infusion methods for receptor quantification: application to [18F] cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13: 24\u201342.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BF1300251_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s002130000623","volume":"154","author":"SD Comer","year":"2001","unstructured":"Comer SD, Collins ED, Fischman MW (2001). Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology 154: 28\u201337.","journal-title":"Psychopharmacology"},{"key":"BF1300251_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1476-5381.1977.tb07532.x","volume":"60","author":"A Cowan","year":"1977","unstructured":"Cowan A, Lewis JW, Macfarlane IR (1977). Agonist and antagonist properties of buprenorphine: a new antinociceptive agent. Br J Pharmacol 60: 537\u2013545.","journal-title":"Br J Pharmacol"},{"key":"BF1300251_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0020-708X(85)90089-4","volume":"36","author":"RF Dannals","year":"1985","unstructured":"Dannals RF, Ravert HT, Frost JJ, Wilson AA, Burns HD, Wagner Jr HN (1985). Radiosynthesis of an opiate receptor binding radiotracer: [11C]carfentanil. Int J Appl Radiat Isot 36: 303\u2013306.","journal-title":"Int J Appl Radiat Isot"},{"key":"BF1300251_CR7","volume-title":"Structured Clinical Interview for DSM-IV Axis Disorders\u2014Patient Edition (SCID-I\/P, Version 2.0)","author":"MB First","year":"1996","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis Disorders\u2014Patient Edition (SCID-I\/P, Version 2.0). Biometrics Research Department, NY State Psychiatric Institute: New York."},{"key":"BF1300251_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hbm.460020402","volume":"2","author":"KJ Friston","year":"1995","unstructured":"Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ (1995). Statistical parametric maps in functional neuroimaging: A general linear approach. Hum Brain Map 2: 189\u2013210.","journal-title":"Hum Brain Map"},{"key":"BF1300251_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/jcbfm.1989.59","volume":"9","author":"JJ Frost","year":"1989","unstructured":"Frost JJ, Douglass KH, Mayberg HS, Dannals RF, Links JM, Wilson AA et al (1989). Multicompartmental analysis of [11C]carfentanil binding to opiate receptors in humans measured by positron emission tomography. J Cereb Blood Flow Metab 9: 398\u2013409.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BF1300251_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/clpt.1990.67","volume":"47","author":"PJ Fudala","year":"1990","unstructured":"Fudala PJ, Jaffe JH, Dax EM, Johnson RE (1990). Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 47: 525\u2013534.","journal-title":"Clin Pharmacol Ther"},{"key":"BF1300251_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1037\/1064-1297.10.1.39","volume":"10","author":"MK Greenwald","year":"2002","unstructured":"Greenwald MK (2002). Heroin craving and drug use in opioid-maintained volunteers: effects of methadone dose variations. Exp Clin Psychopharmacol 10: 39\u201346.","journal-title":"Exp Clin Psychopharmacol"},{"key":"BF1300251_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0376-8716(99)00032-0","volume":"56","author":"MK Greenwald","year":"1999","unstructured":"Greenwald MK, Johanson CE, Schuster CR (1999). Opioid reinforcement in heroin-dependent volunteers during buprenorphine maintenance. Drug Alcohol Depend 56: 191\u2013203.","journal-title":"Drug Alcohol Depend"},{"key":"BF1300251_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s00213-001-0975-0","volume":"160","author":"MK Greenwald","year":"2002","unstructured":"Greenwald MK, Schuh KJ, Hopper JA, Schuster CR, Johanson CE (2002). Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 160: 344\u2013352.","journal-title":"Psychopharmacology"},{"key":"BF1300251_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/00003495-197917020-00001","volume":"17","author":"RC Heel","year":"1979","unstructured":"Heel RC, Brogdon RN, Speight TM, Avery GS (1979). Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 17: 81\u2013110.","journal-title":"Drugs"},{"key":"BF1300251_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","volume":"35","author":"DR Jasinski","year":"1978","unstructured":"Jasinski DR, Pevnick JS, Griffith JD (1978). Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 35: 501\u2013506.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1300251_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0969-8051(01)00226-8","volume":"28","author":"DM Jewett","year":"2001","unstructured":"Jewett DM (2001). A simple synthesis of [11C]carfentanil. Nucl Med Biol 28: 733\u2013734.","journal-title":"Nucl Med Biol"},{"key":"BF1300251_CR17","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","volume":"343","author":"RE Johnson","year":"2000","unstructured":"Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE (2000). A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343: 1290\u20131297.","journal-title":"N Engl J Med"},{"key":"BF1300251_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0376-8716(95)01186-2","volume":"40","author":"RE Johnson","year":"1995","unstructured":"Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE (1995). A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 40: 17\u201325.","journal-title":"Drug Alcohol Depend"},{"key":"BF1300251_CR19","first-page":"1070","volume":"295","author":"MA Kling","year":"2000","unstructured":"Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J et al (2000). Opioid receptor imaging with positron emission tomography and [18F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 295: 1070\u20131076.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300251_CR20","unstructured":"Koeppe RA (1999). Data analysis for PET studies of neuroreceptor modulation. J Nucl Med 5, 287pp."},{"key":"BF1300251_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0024-3205(94)00937-6","volume":"56","author":"K Kristensen","year":"1995","unstructured":"Kristensen K, Christensen CB, Christrup LL (1995). The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 56: 45\u201350.","journal-title":"Life Sci"},{"key":"BF1300251_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1360-0443.1998.93454910.x","volume":"93","author":"JJ Kuhlman Jr","year":"1998","unstructured":"Kuhlman Jr JJ, Levine B, Johnson RE, Fudala PJ, Cone EJ (1998). Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance, and withdrawal from sublingual buprenorphine. Addiction 93: 549\u2013559.","journal-title":"Addiction"},{"key":"BF1300251_CR23","first-page":"103","volume-title":"Advances in Substance Abuse","author":"JW Lewis","year":"1983","unstructured":"Lewis JW, Rance MJ, Sanger DJ (1983). The pharmacology and abuse potential of buprenorphine: a new antagonist analgesic. In: Mello NK (ed). Advances in Substance Abuse Vol. 3 JAI Press: Greenwich, 103\u2013154."},{"key":"BF1300251_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","volume":"93","author":"W Ling","year":"1998","unstructured":"Ling W, Charuvastra C, Collins JF, Batki S, Brown Jr LS, Kintaudi P et al (1998). Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93: 475\u2013486.","journal-title":"Addiction"},{"key":"BF1300251_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang G-J, Ding Y-S, Alexoff DL (1996). Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16: 834\u2013840.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BF1300251_CR26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/00005053-198507000-00005","volume":"173","author":"AT McLellan","year":"1985","unstructured":"McLellan AT, Luborsky L, Cacciola J, Griffith J, Evans F, Barr HL et al (1985a). New data from the Addiction Severity Index. J Nerv Ment Dis 173: 412\u2013423.","journal-title":"J Nerv Ment Dis"},{"key":"BF1300251_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/00005053-198001000-00006","volume":"168","author":"AT McLellan","year":"1985","unstructured":"McLellan AT, Luborsky L, O'Brien CP (1985b). Improved diagnostic instrument for substance abuse patients: The Addiction Severity Index. J Nerv Ment Dis 168: 26\u201333.","journal-title":"J Nerv Ment Dis"},{"key":"BF1300251_CR28","first-page":"30","volume":"223","author":"NK Mello","year":"1982","unstructured":"Mello NK, Mendelson JH, Kuehnle JC (1982). Buprenorphine effects on human heroin self-administration: an operant analysis. J Pharmacol Exp Ther 223: 30\u201339.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300251_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/009127009703700106","volume":"37","author":"J Mendelson","year":"1997","unstructured":"Mendelson J, Upton RA, Everhart ET, Jacob P, Jones RT (1997). Bioavailability of sublingual buprenorphine. J Clin Pharmacy 37: 31\u201337.","journal-title":"J Clin Pharmacy"},{"key":"BF1300251_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S1361-8415(97)85010-4","volume":"1","author":"CR Meyer","year":"1997","unstructured":"Meyer CR, Boes JL, Kim B, Bland PH, Zasadny KR, Kison PV et al (1997). Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1: 195\u2013206.","journal-title":"Med Image Anal"},{"key":"BF1300251_CR31","first-page":"1579","volume":"33","author":"S Minoshima","year":"1992","unstructured":"Minoshima S, Berger KL, Lee KS, Mintun MA (1992). An automated method for rotational correction and centering of three-dimensional functional brain images. J Nucl Med 33: 1579\u20131585.","journal-title":"J Nucl Med"},{"key":"BF1300251_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/ana.410150302","volume":"15","author":"MA Mintun","year":"1984","unstructured":"Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984). A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15: 217\u2013227.","journal-title":"Ann Neurol"},{"key":"BF1300251_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1006\/abio.2002.5673","volume":"306","author":"DE Moody","year":"2002","unstructured":"Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL (2002). A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 306: 31\u201339.","journal-title":"Anal Biochem"},{"key":"BF1300251_CR34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1177\/00912709922008236","volume":"39","author":"RP Nath","year":"1999","unstructured":"Nath RP, Upton RA, Everhart ET, Cheung P, Shwonek P, Jones RT et al (1999). Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 39: 619\u2013623.","journal-title":"J Clin Pharmacol"},{"key":"BF1300251_CR35","first-page":"505","volume":"272","author":"M Ohtani","year":"1995","unstructured":"Ohtani M, Kotaki H, Sawada Y, Iga T (1995). Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 272: 505\u2013510.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300251_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/00498258509045363","volume":"15","author":"RB Pontani","year":"1985","unstructured":"Pontani RB, Vadlamani NL, Misra AL (1985). Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica 15: 287\u2013297.","journal-title":"Xenobiotica"},{"key":"BF1300251_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0376-8716(94)90121-X","volume":"35","author":"MI Rosen","year":"1994","unstructured":"Rosen MI, Wallace EA, McMahon TJ, Pearsall HR, Woods SW, Price LH et al (1994). Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend 35: 141\u2013149.","journal-title":"Drug Alcohol Depend"},{"key":"BF1300251_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/0006-3223(93)90258-F","volume":"34","author":"RS Schottenfeld","year":"1993","unstructured":"Schottenfeld RS, Pakes J, Ziedonis D, Kosten TR (1993). Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry 34: 66\u201374.","journal-title":"Biol Psychiatry"},{"key":"BF1300251_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0376-8716(99)00012-5","volume":"56","author":"KJ Schuh","year":"1999","unstructured":"Schuh KJ, Johanson CE (1999). Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend 56: 55\u201360.","journal-title":"Drug Alcohol Depend"},{"key":"BF1300251_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1037\/1064-1297.3.4.424","volume":"3","author":"CR Schuster","year":"1995","unstructured":"Schuster CR, Greenwald MK, Johanson CE, Heishman SJ (1995). Measurement of drug craving during naloxone-precipitated withdrawal in methadone maintained volunteers. Exp Clin Psychopharmacol 3: 424\u2013431.","journal-title":"Exp Clin Psychopharmacol"},{"key":"BF1300251_CR41","doi-asserted-by":"crossref","unstructured":"Tiffany ST, Fields L, Singleton E, Haertzen C, Henningfield JE (1995, unpublished data). The development of a heroin craving questionnaire.","DOI":"10.1037\/t01505-000"},{"key":"BF1300251_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0014-2999(89)90582-7","volume":"167","author":"M Titeler","year":"1989","unstructured":"Titeler M, Lyon RA, Kuhar MJ, Frost JF, Dannals RF, Leonhardt S et al (1989). Mu opiate receptors are selectively labelled by [3H]carfentanil in human and rat brain. Eur J Pharmacol 167: 221\u2013228.","journal-title":"Eur J Pharmacol"},{"key":"BF1300251_CR43","first-page":"361","volume":"274","author":"SL Walsh","year":"1995","unstructured":"Walsh SL, Preston KL, Bigelow GE, Stitzer ML (1995). Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274: 361\u2013372.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300251_CR44","first-page":"12","volume":"121","author":"JH Woods","year":"1992","unstructured":"Woods JH, France CP, Winger GD (1992). Behavioral pharmacology of buprenorphine: issues relevant to its potential in treating drug abuse. NIDA Res Monogr 121: 12\u201327.","journal-title":"NIDA Res Monogr"},{"key":"BF1300251_CR45","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0893-133X(00)00110-X","volume":"23","author":"JK Zubieta","year":"2000","unstructured":"Zubieta JK, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM et al (2000). Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 23: 326\u2013334.","journal-title":"Neuropsychopharmacology"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/1300251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300251","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T02:44:36Z","timestamp":1684205076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1300251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,30]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["BF1300251"],"URL":"https:\/\/doi.org\/10.1038\/sj.npp.1300251","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,30]]}}}